UK Markets close in 1 hr 42 mins

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.29+0.35 (+4.35%)
As of 09:42AM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • l
    lozo
    Did you guys see this new trading strategy.For more info http://hiddenwealth.tech/
  • R
    Reisdorfer
    I love starting my day with the daily emails from  http://bullishstocks.tech.. They equip me with what I need to make wiser investment decisions!
  • P
    PRIDGEN
    CVAC looks like it is about to drop. Be careful guys. I have been reading www.daytradercompany.tech and their stocks have been doing way better.
  • L
    Loper
    CureVac is focusing on mRNA cancer vaccines, CFO says
    https://twitter.com/aktienboersen/status/1572170373533409281
  • J
    Jassi
    The market is about to get crushed...Are you prepared? do this now.Check out http://cryptosecret.tech
  • W
    Warren
    If Anybody know who buy 500,000 shares of CVAC ?
  • S
    Samantha
    MASSIVE order are coming in at the close, huge volume. Large institutions on the move again🤑🚀Deposit this sell of today, we had a very good week in this volatile market good volume at the close and A /Hs💯 is you would like to get on call Number is 👉+1 2703803076
  • I
    Ivan Stojanovic
    Any news about CVAC
  • n
    nito
    Virosomes as a carrier delivery system for mRNA or adeno virus vector based vaccine candidates $jnj $mrna $bntx $ctlt $mymx

    mRNA based vaccines have proven successful in curbing the global COVID-19 pandemic particularly in higher income countries. Current vaccines are formulated in lipid nanoparticles but require a restrictive cold-chain (-15°C to-60°C) which may be not feasible commercially/ logistically when compared to other subunit vaccines approaches typically stored at 4-8 °C. Virosomes are an alternative carrier system commercialised with good safety and efficacy data for Hepatitis A (Epaxal) and Influenza (Inflexal) vaccines.

    Project Context and Objectives:
    The aim of this project will be to evaluate the feasibility of incorporating candidate mRNA sequences of various sizes into virosomes through different methods including encapsulation, surface linkage and with linkers. The potency and long-term stability of these virosomes will then be evaluated and also formulated for enhanced stability.

    Knowledge gained from this project could offer valuable tools that may also be applied to other virosome-based therapies, such as gene therapies.

    Results will be presented at regular meetings with the supervisory team, at conferences and published in peer-reviewed journals.
  • E
    Edelstein
    (VAXX) $2.25 ..Potential BEST Vaccine for Covid Prevention with final Phase 3 results in early Q4 and a Alzheimer Vaccine which is Phase 2b ready = this could be the biggest opp of ALL Covid stocks ...GLTA
    "The Phase 3 heterologous boost study evaluating UB-612 against COVID-19 in subjects who have received primary immunization from mRNA, adenovirus vector, or inactivated viral vaccines is ongoing. Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications."

    ####
  • d
    divesdeeper
    Does anyone here think suing Pfizer is a good use of CVAC's cash. Even if they did win it would be years until they see a dollar. Why not focus resources on pipeline development. Seems like a superficial stock pump move IMO.
  • G
    GOP.DowJones6500
    SELL
  • A
    Asyan
    CureVac will produce Monkeyprox Vaccine
  • D
    Deiro
    Got this at $40, any hope?
  • P
    Paul
    It seams CVAC has stopped all clinical trials for COVID vaccine development. The others is long way to go. This company has very bad management team who led the failure of COVID vaccine. It is so hard to get another good market opportunity like COVID pandemic.